drugset / Trial / NCT02537600
Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine wether cobimetinib + vemurafenib combination treatment is effective in the treatment of BRAFV600-mutated melanoma patients with brain metastasis
Timeline
- Start
- 2015-12
- Primary completion
- 2019-11-06
- Completion
- 2019-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |